TA Associates, a leading global growth private equity firm, announced on January 18 that it completed a strategic growth investment in Synokem Pharmaceuticals Ltd.
TA Associates was represented by AZB & Partners. BDA Partners acted as the financial adviser to Synokem. Synokem’s founders will continue as shareholders in Synokem alongside TA. Financial terms of the transaction were not disclosed.
Founded in 1983, Synokem Pharmaceuticals is one of India’s leading contract development and manufacturing organizations (CDMOs), serving customers in the branded generic domestic formulations market. Synokem is based in New Delhi, India, with manufacturing and R&D facilities in Haridwar, India. The company’s products are exported to more than 30 countries.
TA Associates has invested in more than 560 companies around the world and raised more than $48.6 billion in capital since its founding in 1968. It leads buyouts and minority recapitalizations in the technology, financial services, business, healthcare and consumer industries.
According to data captured in the LevinPro HC database, this was the second CDMO transaction of 2023, as of January 18, 2022. This is a notable decrease from January 1, 2022, through January 18, 2022, when there were six CDMO deals. There were 39 CDMO deals announced during 2022.
